This page contains details about ViiV Healthcare clinical trials. Approved prescribing information must continue to guide appropriate use of ViiV Healthcare medicines. This information may vary from country to country. Before prescribing any product mentioned in this section, Healthcare Professionals should consult prescribing information approved in their country.


The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance.

Discover more about the BRIGHTE study and access relevant reference information on the ViiV clinical study register

NP-GBL-HVX-WCNT-220013 April 2022